Statin-related Muscle Toxicity: An Evidence-based Review.

TouchREVIEWS in endocrinology Pub Date : 2022-11-01 Epub Date: 2022-11-21 DOI:10.17925/EE.2022.18.2.89
Mohammad S Jeeyavudeen, Joseph M Pappachan, Ganesan Arunagirinathan
{"title":"Statin-related Muscle Toxicity: An Evidence-based Review.","authors":"Mohammad S Jeeyavudeen, Joseph M Pappachan, Ganesan Arunagirinathan","doi":"10.17925/EE.2022.18.2.89","DOIUrl":null,"url":null,"abstract":"<p><p>The efficacy of statins in the primary and secondary prevention of cardiovascular disease has been proven beyond doubt. The number needed to treat to prevent one cardiovascular event is 1 in 30 over 10 years, and the number needed to treat for secondary prevention is much lower. However, a recent study demonstrated that only 68% of eligible patients are on statin therapy. Moreover, there seems to be a reluctance to escalate statin doses due to the fear of adverse effects. The adverse effects that worries patients and their physicians most frequently are those related to muscular symptoms. N-of-1 trial evidence suggests that muscular symptoms attributed to statins are often caused by the nocebo effect. This article aims to provide a structured, evidence-based approach to suspected statin-related muscle toxicity.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"18 2","pages":"89-95"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835810/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TouchREVIEWS in endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EE.2022.18.2.89","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The efficacy of statins in the primary and secondary prevention of cardiovascular disease has been proven beyond doubt. The number needed to treat to prevent one cardiovascular event is 1 in 30 over 10 years, and the number needed to treat for secondary prevention is much lower. However, a recent study demonstrated that only 68% of eligible patients are on statin therapy. Moreover, there seems to be a reluctance to escalate statin doses due to the fear of adverse effects. The adverse effects that worries patients and their physicians most frequently are those related to muscular symptoms. N-of-1 trial evidence suggests that muscular symptoms attributed to statins are often caused by the nocebo effect. This article aims to provide a structured, evidence-based approach to suspected statin-related muscle toxicity.

Abstract Image

Abstract Image

他汀类药物相关肌肉毒性:基于证据的综述。
他汀类药物在心血管疾病一级和二级预防中的疗效已被证明是毋庸置疑的。在 10 年内预防一次心血管事件所需的治疗人数为 30 分之 1,而二级预防所需的治疗人数要低得多。然而,最近的一项研究表明,只有 68% 的合格患者在接受他汀类药物治疗。此外,由于担心不良反应,人们似乎不愿意增加他汀类药物的剂量。最让患者及其医生担心的不良反应是与肌肉症状有关的不良反应。N-of-1试验证据表明,他汀类药物引起的肌肉症状通常是由 "预兆效应"(nocebo effect)引起的。本文旨在为怀疑他汀类药物相关的肌肉毒性提供一种结构化的循证方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信